Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qijia Fuzheng Rougan is a traditional Chinese medicine (TCM) compound formula primarily investigated for its effects on liver fibrosis and related hepatic diseases. The formulation consists of multiple herbal components designed to regulate immune responses and inhibit fibrogenesis in the liver. Mechanistically, it ameliorates extracellular matrix (ECM) deposition in hepatic fibrosis by modulating the JAK1/STAT6-microRNA-23a feedback loop in macrophage M2 polarization[1][4][6]. It also inhibits aberrant activation of mTORC1 signaling to reverse macrophage M1 to M2 polarization and reduces pro-inflammatory cytokines such as CCL2, CCL5, IL-1β, IL-6, inducible nitric oxide synthase (iNOS), and TNF-α[3]. The formula further decreases markers of liver fibrosis including collagen I/III, lysyl oxidase, TIMP1, α-smooth muscle actin (α-SMA), transforming growth factor β (TGF-β), and hypoxia-inducible factor 1α through pathways like PI3K/AKT[3]. Its primary indication is for the treatment or mitigation of hepatic fibrosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qijia fuzheng rougan.